Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study

Wang, Xiaodong; Cheng, Hao‐Tsai; Hua, Rongrong; Yang, Jing; Dai, Guohao; Zhang, Zan; Wang, Renzhi; Qin, Chuan; An, Yu

doi:10.1016/j.jcyt.2013.06.001

Cited by 70 publications

(56 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On follow-up after 6 months, the gross motor function measure (GMFM) score in these patients were significantly higher and there were no serious adverse events noted. Similar results were observed in a study carried out by Wang et al 31 …”

supporting

confidence: 92%

Clinical neurorestorative progresses in cerebral palsy

Sharma¹,

Geng²,

Sane³

et al. 2017

View full text Add to dashboard Cite

Cerebral palsy (CP), group of permanent nonprogressive clinical disorders in children, is caused by damage to the immature brain. Conventionally available treatments for CP are mainly targeted toward management of its symptoms. With the upcoming field of neurorestorative strategies, we are now able to repair the core brain damage in CP. There are various drugs, stem cells, etc, which have been implicated to have neurorestorative properties. Autologous bone marrow stem cells, umbilical cord stem cells, neural stem cells, and olfactory ensheathing cells have shown the safety and efficacy in preliminary studies. Here, we review the different medicines and cell types that have shown beneficial effects in clinical studies. We propose that combination strategies may be the future of neurorestoration.

show abstract

supporting

confidence: 92%

Clinical neurorestorative progresses in cerebral palsy

Sharma¹,

Geng²,

Sane³

et al. 2017

View full text Add to dashboard Cite

show abstract

“…MSCs also showed great results when transplanted with T cells, controlling inflammatory activity in order to create the proper microenvironment for cell transplantation [24] . The immunomodulating effect of MSCs has also been reported in other clinical trials and MSCs have been shown to play an important role as immunomodulators and angiogenic agents in drug resistant patients as well as in patients with cerebral palsy, critical limb ischemia and kidney transplants [25][26][27][28][29][30][31][32] . In another study conducted with 40 patients, bone regeneration was achieved when a great number of CD34 + cells were transplanted to the lesion site, 20 patients achieved mature bone regeneration, even in the group that received a low number of cells 4 patients achieved bone regeneration.…”

Section: Mesenchymal Stem Cells/bone Marrow Stem Cellsmentioning

confidence: 78%

Adult stem cells in neural repair: Current options, limitations and perspectives

Mariano¹

2015

WJSC

View full text Add to dashboard Cite

Stem cells represent a promising step for the future of regenerative medicine. As they are able to differentiate into any cell type, tissue or organ, these cells are great candidates for treatments against the worst diseases that defy doctors and researchers around the world. Stem cells can be divided into three main groups: (1) embryonic stem cells; (2) fetal stem cells; and (3) adult stem cells. In terms of their capacity for proliferation, stem cells are also classified as totipotent, pluripotent or multipotent. Adult stem cells, also known as somatic cells, are found in various regions of the adult organism, such as bone marrow, skin, eyes, viscera and brain. They can differentiate into unipotent cells of the residing tissue, generally for the purpose of repair. These cells represent an excellent choice in regenerative medicine, every patient can be a donor of adult stem cells to provide a more customized and efficient therapy against various diseases, in other words, they allow the opportunity of autologous transplantation. But in order to start clinical trials and achieve great results, we need to understand how these cells interact with the host tissue, how they can manipulate or be manipulated by the microenvironment where they will be transplanted and for how long they can maintain their multipotent state to provide a full regeneration.

show abstract

“…No adverse event was reported by the treatment protocol. The study of Wang et al (16) Another study published by Shroff et al (19) in India during year 2014 on 91 patients in the age range of 2 to 18 years, who underwent a four-phase human embryonic stem cell therapy and followed for 1 to 2 months, assessed the final improvement in motor functional status. In their study, during phase 1 (including 91 patients), 0.25 mL of Human Embryonic Stem Cells (hESCs) were administered intramuscularly once daily plus 1 mL of hESC intravenously twice every 7 days for a total of 8 weeks.…”

Section: Resultsmentioning

confidence: 99%

“…On the other hand, stem cell therapy with the different protocols, including autologous MSC therapy or human embryonic stem cell therapy, could result in an increase of motor function in patients with CP. However, considering these assessed trials, indicated a significant heterogeneity between the studies (15)(16)(17)(18)(19). In fact, because of the difference in treatment protocols as well as different gap periods between treatment phases, the change in motor function was found to be widely varied between the studies.…”

Section: Discussionmentioning

confidence: 99%

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

et al. 2018

View full text Add to dashboard Cite

The current knowledge on how to use stem cells therapeutically for improving motor function in patients with cerebral palsy is growing. The present review aimed at assessing clinical trials related to beneficial effects of stem cells in patients with cerebral palsy. Electronic searches including "stem cell" and "cerebral palsy" as keywords were conducted using PubMed, Ovid, Web of Science, Scopus, Cochrane library, and CINAHL till February 2016. Two assessors reviewed the methodological quality and eligibility of the retrieved articles, independently. Among 77 studies initially reviewed based on the keywords, only 6 clinical trials were identified that met the inclusion criteria. Pooled response rate of stem cell therapy to treat cerebral palsy was estimated by assessing the percentage of improvement with a gross motor function classification system score. The resulting pooled estimate indicated a 30.7% (95% CI: 25.80% to 35.69%) increase in the score, 1 to 6 months after cell transplantation. In this regard, the test for heterogeneity was statistically significant (I2 = 87.9%, χ 2 = 41.22, P < 0.0001). Stem cell therapy has the potential to improve motor function in patients with cerebral palsy. However, promising results from limited studies warrant further research.

show abstract

Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study

Cited by 70 publications

References 37 publications

Clinical neurorestorative progresses in cerebral palsy

Clinical neurorestorative progresses in cerebral palsy

Adult stem cells in neural repair: Current options, limitations and perspectives

A Review on Stem Cell Therapy in Cerebral Palsy with a Focus on Motor Function Improvement

Contact Info

Product

Resources

About